{
    "id": 415,
    "fullName": "AKT1 E17K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "AKT1 E17K lies within the PH domain of the Akt1 protein (UniProt.org). E17K leads to constitutive activation of Akt1, activates downstream signaling, and is transforming in culture (PMID: 17611497, PMID: 29533785, PMID: 27147599, PMID: 26701849).",
            "references": [
                {
                    "id": 9005,
                    "pubMedId": 17611497,
                    "title": "A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17611497"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5969,
                    "pubMedId": 26701849,
                    "title": "Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26701849"
                },
                {
                    "id": 6273,
                    "pubMedId": 27147599,
                    "title": "Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27147599"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 207,
        "geneSymbol": "AKT1",
        "terms": [
            "AKT1",
            "AKT",
            "CWS6",
            "PKB",
            "PKB-ALPHA",
            "PRKBA",
            "RAC",
            "RAC-ALPHA"
        ]
    },
    "variant": "E17K",
    "createDate": "04/24/2014",
    "updateDate": "08/23/2018",
    "referenceTranscriptCoordinates": {
        "id": 166876,
        "transcript": "NM_001014432",
        "gDna": "chr14:g.104780214C>T",
        "cDna": "c.49G>A",
        "protein": "p.E17K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11433,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two patients with endometrial cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3622,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5592,
                "name": "breast papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3621,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 6212,
                "name": "ovarian endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17213,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BAY 1125976 treatment demonstrated safety and pharmacological inhibition of Akt signaling, and resulted in a stable disease in 33.3% (3/9) of hormone receptor-positive breast cancer patients harboring AKT1 E17K in the dose expansion study, however, AKT1 E17K mutation status was not associated with response (PMID: 31835495; NCT01915576).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17786,
                    "pubMedId": 31835495,
                    "title": "Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31835495"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17304,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Miransertib (ARQ092) treatment resulted in complete tumor remission and improved quality of life in a patient harboring AKT1 E17K who had Proteus syndrome and developed ovarian carcinoma, and treatment was ongoing at 22 months (PMID: 31058421).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15350,
                    "pubMedId": 31058421,
                    "title": "First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31058421"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11452,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 2999,
                "name": "granulosa cell tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15220,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capivasertib (AZD5363) treatment resulted in confirmed partial response in 20% (4/20) and unconfirmed partial response in 10% (2/20) of patients with ESR1-positive breast cancer harboring AKT1 E17K (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10809,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8844,
                    "pubMedId": 24735930,
                    "title": "Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24735930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17742,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, MK2206 treatment resulted in no objective response in 4 patients with advanced breast cancer harboring AKT1 E17K (PMID: 31277699; NCT01277757).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15758,
                    "pubMedId": 31277699,
                    "title": "Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31277699"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10278,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to Miransertib (ARQ092), demonstrating inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3633,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capivasertib (AZD5363) inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11432,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, four patients with ESR1-positive breast cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15217,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with uterus leiomyosarcoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5289,
                "name": "uterus leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11435,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with triple-receptor negative breast cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10807,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with Capivasertib (AZD5363) (PMID: 28376212).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 7212,
                "name": "meningothelial meningioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8837,
                    "pubMedId": 28376212,
                    "title": "Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28376212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3828,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 50688,
                "name": "anal canal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2275,
                    "pubMedId": null,
                    "title": "Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/3685"
                },
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10279,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 4331,
                "therapyName": "ARQ 751",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11434,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with cervical cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15216,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) of patients with advanced solid tumors harboring AKT1 E17K mutation, 6 of the patients achieved partial response had hormone receptor-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8807,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15218,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in stable disease over 21 months in a patient with an oncocytic carcinoma of the parotid gland harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9036,
                "name": "parotid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9713,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7487,
                    "pubMedId": 27872130,
                    "title": "A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872130"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11436,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with lung adenocarcinoma harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1336,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capivasertib (AZD5363) demonstrated safety and preliminary antitumor activity in patients with advanced solid tumors, resulted in stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343; NCT01353781).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1049,
                    "pubMedId": null,
                    "title": "459P A Phase I study to assess the safety and tolerability of the selective Akt inhibitor AZD5363 in Japanese patients with advanced solid tumours",
                    "url": "http://annonc.oxfordjournals.org/content/25/suppl_4/iv153.1.full.pdf"
                },
                {
                    "id": 5230,
                    "pubMedId": 26931343,
                    "title": "Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26931343"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15215,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) and stable disease in 46% (16/35) of patients with advanced solid tumors harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15219,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with endometrioid adenocarcinoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 2870,
                "name": "endometrial adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12850,
                    "pubMedId": 30429128,
                    "title": "Capivasertib Active against AKT1-Mutated Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30429128"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1227,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3614,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 100% (2/2) of colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",
            "molecularProfile": {
                "id": 13841,
                "profileName": "AKT1 E17K BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1874,
                "therapyName": "Cetuximab + Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3888,
                    "pubMedId": 25714871,
                    "title": "AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25714871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).",
            "molecularProfile": {
                "id": 14066,
                "profileName": "AKT1 E17K FGFR3 Y373C"
            },
            "therapy": {
                "id": 3346,
                "therapyName": "AZD4547 + Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",
            "molecularProfile": {
                "id": 16525,
                "profileName": "AKT1 E17K NRAS Q61R"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2275,
                    "pubMedId": null,
                    "title": "Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/3685"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26172,
                "profileName": "AKT1 E17K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8810,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",
            "molecularProfile": {
                "id": 26446,
                "profileName": "AKT1 E17K NRAS G12D"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3634,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-2206 inhibited growth and colony formation of a triple negative human breast cancer cell line harboring AKT E17K in culture and inhibited tumor growth in xenograft models (PMID: 26351323).",
            "molecularProfile": {
                "id": 26602,
                "profileName": "AKT1 E17K ERBB2 neg ESR1 neg PGR neg"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3912,
                    "pubMedId": 26351323,
                    "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11438,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a cervical cancer patient harboring AKT1 E17K, FGFR3 S249C, and an NF1 inactivating mutation demonstrated a durable partial response with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 28034,
                "profileName": "AKT1 E17K FGFR3 S249C NF1 inact mut"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11439,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a breast cancer patient harboring AKT1 E17K and an NF1 inactivating mutation demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).",
            "molecularProfile": {
                "id": 28035,
                "profileName": "AKT1 E17K NF1 inact mut"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 643,
            "profileName": "AKT1 E17K",
            "profileTreatmentApproaches": [
                {
                    "id": 11423,
                    "name": "Akt1 Inhibitor",
                    "profileName": "AKT1 E17K"
                },
                {
                    "id": 11424,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "AKT1 E17K"
                }
            ]
        },
        {
            "id": 13841,
            "profileName": "AKT1 E17K BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14066,
            "profileName": "AKT1 E17K FGFR3 Y373C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14067,
            "profileName": "AKT1 E17K ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16525,
            "profileName": "AKT1 E17K NRAS Q61R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26172,
            "profileName": "AKT1 E17K BRAF V600X PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26446,
            "profileName": "AKT1 E17K NRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26602,
            "profileName": "AKT1 E17K ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28034,
            "profileName": "AKT1 E17K FGFR3 S249C NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28035,
            "profileName": "AKT1 E17K NF1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 166878,
            "transcript": "NM_005163",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166877,
            "transcript": "XM_005267401",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166882,
            "transcript": "XM_017021075",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166879,
            "transcript": "XM_017021078",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166880,
            "transcript": "XM_017021077",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166875,
            "transcript": "NM_001014431",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166876,
            "transcript": "NM_001014432",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 166881,
            "transcript": "XM_017021076",
            "gDna": "chr14:g.104780214C>T",
            "cDna": "c.49G>A",
            "protein": "p.E17K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}